Colloidal Bismuth Pectin

DRUG8 trials

Sponsors

Shandong University, Second Affiliated Hospital, School of Medicine, Zhejiang University, Nanjing First Hospital, Nanjing Medical University

Conditions

Antimicrobial Susceptibility TestingHelicobacter Pylori EradicationHelicobacter Pylori Infection

Early Phase 1

The Efficacy and Safety of Keverprazan for Helicobacter Pylori Eradication

Not yet recruitingNCT06777732

Nanjing First Hospital, Nanjing Medical UniversityHelicobacter Pylori Infection

Start: 2025-03-31End: 2026-01-31Target: 672Updated: 2025-01-16

Phase 4

Antimicrobial Susceptibility Testing Guided Therapy Versus Empirical Therapy for the First-line Helicobacter Pylori Eradication.

Shandong UniversityAntimicrobial Susceptibility Testing, Helicobacter Pylori Infection

Start: 2018-07-01End: 2020-01-30Target: 400Updated: 2018-06-27

Effectiveness of Minocycline-Containing Bismuth Quadruple Therapy for Helicobacter Pylori Eradication

Second Affiliated Hospital, School of Medicine, Zhejiang UniversityHelicobacter Pylori Eradication

Start: 2022-01-05End: 2022-12-05Target: 339Updated: 2022-01-13

Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days

Shandong UniversityHelicobacter Pylori Infection

Start: 2021-06-30End: 2023-08-31Target: 1300Updated: 2021-05-25

Efficacy and Safety of Vonoprazan as First-line Treatment for Helicobacter Pylori Eradication

Second Affiliated Hospital, School of Medicine, Zhejiang UniversityHelicobacter Pylori Infection

Start: 2021-05-18End: 2022-04-13Target: 234Updated: 2021-06-01

Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication

CompletedNCT05049902

Shandong UniversityHelicobacter Pylori Infection

Start: 2021-09-21End: 2023-06-30Updated: 2023-07-19

Efficacy and Safety of Dual Therapy as First-line Treatment for Hp Infection

Second Affiliated Hospital, School of Medicine, Zhejiang UniversityHelicobacter Pylori Infection

Start: 2022-08-01End: 2023-08-01Target: 393Updated: 2023-02-16

Bismuth-containing Quadruple Therapy for Helicobacter Pylori First-line Treatment of Different Tetracycline Doses

CompletedNCT05431075

Shandong UniversityHelicobacter Pylori Infection

Start: 2022-07-01End: 2024-02-01Updated: 2024-03-27

Related Papers

Tetracycline Three Times Daily Versus Four Times Daily in Bismuth‐Containing Quadruple Therapy as the First‐Line Treatment of <i>Helicobacter pylori</i> Infection: A Multicenter, Noninferiority, Randomized Controlled Trial

Helicobacter2024-07-012 citations

Bismuth-Containing Quadruple Therapy for Helicobacter pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days.

2024-05-0312 citations

Quadruple therapy with vonoprazan 20 mg daily as a first‐line treatment for <i>Helicobacter pylori</i> infection: A single‐center, open‐label, noninferiority, randomized controlled trial

Helicobacter2022-12-0146 citations